Literature DB >> 6248207

Isolation of an inhibitor of type II interferon induction from tumor ascitic fluids.

S Matsubara, M Suzuki, M Nakamura, K Edo, N Ishida.   

Abstract

A low-molecular-weight fraction (M.W. approximately 700) that specifically impairs the induction of type II interferon in mice by purified protein derivative of tuberculin or OK-432 was isolated from the cell-free ascitic fluid of mice bearing Ehrlich ascites carcinoma. Purification was achieved by ultrafiltration and gel filtration. The inhibitory activity of the isolated fraction was 10 times greater than that of the unfractionated starting material in the impairment of type II interferon induction. The significant inhibition was observed even when 0.2 ml of the 10,000-fold dilution of the fraction, which was previously adjusted to 0.25 A unit at 290 nm absorption, was once treated i.p. in normal mice 48 hr before challenge of type II interferon inducers. This fraction was stable to heating at 56 degrees for 60 min. The active component, however, did not affect the in vivo induction of type I interferon by polyriboinosinic-polyribocytidylic acid or tilorone-HCl. In parallel experiments, an identical low-molecular-weight fraction that impairs the type II interferon induction in mice was isolated from the ascitic fluids of rats bearing AH-100B ascites tumor and from a human hepatoma case with advanced cancer metastatic to the peritoneal cavity. However, nontumorous ascitic fluids obtained from adjuvant-stimulated mice and a human liver cirrhosis case did not contain any such inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248207

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Effects of L2C leukemia on macrophage-mediated responses.

Authors:  D P Collins
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 2.  The hormonal concept of interferon. Brief review.

Authors:  A D Inglot
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

3.  Inhibition of cytokine production by a tumor cell product.

Authors:  E Farram; M Nelson; D S Nelson; D K Moon
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

4.  Human tumour-induced inhibition of interferon action in vitro: reversal of inhibition by beta-carotene (pro-vitamin A).

Authors:  J Rhodes; P Stokes; P Abrams
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Serum interferon levels in patients having radiotherapy for cervical carcinoma.

Authors:  F von Rheinbaben; U D Koenig; K E Schneweis
Journal:  Arch Gynecol       Date:  1983

6.  Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour.

Authors:  L C McIntosh; L M Morrice; Y Udagawa; A W Thomson
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

7.  Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.

Authors:  J Rhodes; D H Jones; N M Bleehen
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.